You are about to leave a Sanofi U.S. website.

Sanofi Promise: A Warranty Program for CABLIVI | CABLIVI reimbursement

Prescribe CABLIVI with confidence

Sanofi is committed to individuals living with acquired thrombotic thrombocytopenic purpura (aTTP/iTTP)
and the healthcare professionals who support them.

As part of this commitment, the cost of CABLIVI will be refunded in the hospital setting for up to six (6) inpatient doses for patients who fail to reach initial clinical response to CABLIVI or up to twelve (12) inpatient doses for patients who exacerbate while on CABLIVI treatment, as defined by the program terms. Additional Eligibility Requirements, Terms and Conditions apply. CABLIVI must be administered according to the FDA-approved label (Prescribing Information). Refund amount will be up to the wholesale acquisition cost (WAC) or actual acquisition cost, whichever is less.

If a patient is non-responsive to CABLIVI treatment within the inpatient setting, your institution may be eligible for a refund

Eligibility overview

CABLIVI must be administered in the US and prescribed according to its FDA-approved label (Prescribing Information). CABLIVI treatment must be discontinued at the discretion of the healthcare provider for one of the following reasons:

• Failure to Reach Initial Clinical Response: Patient experienced platelet counts <50 × 10⁹/L, after 4 days of combined treatment with CABLIVI, PEX, and immunosuppressive therapy
• Exacerbation: Patient experienced a new drop in platelet count after initial platelet count normalization (>150 × 10⁹/L), necessitating re‑initiation of PEX after having ruled out any causes for the drop in platelet count other than aTTP pathophysiology

Additional Eligibility Requirements, Terms and Conditions apply. Please see the full Terms and Conditions below.

FILING A CLAIM

To file a claim, you must fully complete and sign the Warranty Claim Form, Hospital Declarations and Authorizations Form, and Physician Attestation Form available below within 90 days following the patient becoming a non-responder to CABLIVI.

You can submit the forms by:
EMAIL: SanofiPromise@aig.com
FAX: 1-715-342-2405
MAIL: AIG Claims, Inc., PO Box 845, Stevens Point, WI 54481-0047

To successfully file a claim, the following 3 forms must be completed and submitted:

Warranty Claim Form

Captures information required to file a claim.

Download

Hospital Declarations and
Authorizations Form

Certifies use of CABLIVI was aligned with Terms and Conditions of the program.

Download

Physician Attestation Form

Summarizes physician information and consents.

Download

Terms and Conditions

Sanofi (referred to as “us”, “we” and similar terms) is proud to offer the Sanofi Promise Warranty Program for CABLIVI (the “Program”) to each institution that purchases CABLIVI (referred to as “you”, “your” and similar terms) and who meets the Eligibility Requirements and follows the Benefit Request Process described below (the “Terms”). You should carefully review these Terms. Coverage is subject to certain terms, conditions, and limitations, including limitations on the amount of coverage.

Overview of Program

For institutions who meet the Eligibility Requirements, the cost of CABLIVI will be refunded for up to six (6) inpatient doses for patients who fail to reach initial clinical response to CABLIVI or up to twelve (12) inpatient doses for patients who exacerbate while on CABLIVI treatment. Refund amount will be up to wholesale acquisition cost (WAC) or actual acquisition cost, whichever is less.

Medication Eligible for the Program

CABLIVI (caplacizumab-yhdp)

Eligibility Requirements

In order for you to be eligible to use the Program, you must satisfy all of the criteria listed below:

1. CABLIVI was administered in the 50 United States or the District of Columbia (U.S. territories and possessions are not eligible) to a patient within the inpatient/institutional setting.
2. CABLIVI was administered, as prescribed by a health care provider, in accordance with its Food and Drug Administration (FDA) Prescribing Information, for the treatment of an adult patient with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
3. CABLIVI treatment was discontinued at the discretion of the health care provider for one of the following reasons qualifying the patient as a non‑responder:
   • Failure to Reach Initial Clinical Response: Patient experienced platelet counts <50 x 10⁹/L, after 4 days of combined treatment with CABLIVI, therapeutic plasma exchange and immunosuppressive therapy. A maximum of six (6) inpatient doses may be refunded for such a non-responder patient.
   • Exacerbation: Patient experienced a new drop in platelet count after initial platelet count normalization (>150 x 10⁹/L), necessitating re‑initiation of therapeutic plasma exchange after having ruled out any causes for the drop in platelet count other than aTTP pathophysiology. A maximum of twelve (12) inpatient doses may be refunded for such a non-responder patient for doses administered prior to drop in platelet count.
   Discontinuation solely due to patient or institution choice, financial considerations, or any other reason does not qualify for the Program.
4. You purchased all doses of CABLIVI administered to the patient directly from a Sanofi authorized distributor.
5. You have not requested reimbursement from any third party (e.g., insurance company, Medicaid, Medicare, patient, etc.) for the acquisition cost of CABLIVI treatment subject to the Warranty.
6. CABLIVI treatment administered in an out-patient setting is not eligible for the Warranty.
7. The first dose of CABLIVI must be administered on or after January 1, 2023 and on or before June 30, 2023 (the “Coverage Period”).
8. You must submit proof of purchase and acquisition cost for all CABLIVI doses subject to the warranty claim.
9. Institution must submit all Claims Information (as described below) within ninety (90) days following the patient becoming a non-responder to CABLIVI.
10. Costs other than for the acquisition price of CABLIVI will not be reimbursed (i.e., administration costs).
11. You (unless you are a Federal health care program beneficiary as defined in 42 CFR § 1000.10) will fully and accurately report the amount refunded to you as part of the Program in the applicable cost reporting mechanism or claim for payment filed with the Department of Health and Human Services or a state Medicaid agency. Furthermore, you will provide, upon request by the Secretary of the Department of Health and Human Services or a state Medicaid agency, information provided to by us or our partners regarding the amount returned to you under the Program.

Benefit Request Process:

In order to be eligible for a refund under this Program, you must satisfy the requirements above and submit the information below (the “Claims Information”), within ninety (90) days following the patient becoming a non-responder to CABLIVI.

1. Call 1-800-295-4010 and a representative will provide you with a Warranty Claim Form, a Hospital Declarations and Authorizations Form, and a Physician Attestation Form, or these forms may be downloaded on this website.
2. You will then need to return a fully completed and signed (i) Warranty Claim Form, (ii) Hospital Declarations and Authorizations Form, and (iii) Physician Attestation Form in accordance with their instructions. Claims can be emailed to SanofiPromise@aig.com, faxed directly to 1-715-342-2405 or sent via mail to AIG Claims, Inc., PO Box 845, Stevens Point, WI 54481-0047.
3. If your Claims Information passes the verification process, we will notify you via telephone, email, or mail that you have been approved for coverage.
4. If your Claims Information does not pass the verification process, we will notify you via email that your Request has been denied and the email will include the reason for the denial (such as, incomplete information, mismatched information, etc.). You will be given the opportunity to resubmit your Claims Information within thirty (30) days of the email notification.

Additional Terms and Conditions

1. We reserve the right to modify the processes, procedures, parameters, or other terms of the Program, or terminate the Program entirely, at any time, without prior notice to you. If we terminate the Program, we will continue to honor valid claims related to initial doses of CABLIVI, prescribed by the physician, dispensed during the Coverage Period, unless prohibited by law. The current status of the Program and applicable terms are available on this website.

LIMITATION OF LIABILITY

IN NO EVENT, UNDER ANY CAUSE OF ACTION OF THEORY OF LIABILITY, SHALL SANOFI, ITS DISTRIBUTORS OR SUPPLIERS BE LIABLE TO YOU OR ANY THIRD PARTY FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, OF ANY NATURE WHATSOEVER, ARISING OUT OF OR IN CONNECTION WITH THE PROGRAM, EVEN IF SANOFI HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

NOTWITHSTANDING ANY DAMAGES THAT YOU MIGHT INCUR FOR ANY REASON WHATSOEVER INCLUDING, WITHOUT LIMITATION, ALL DAMAGES REFERENCED HEREIN AND ALL DIRECT OR GENERAL DAMAGES IN CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, THE ENTIRE AGGREGATE LIABILITY OF SANOFI AND ANY OF ITS DISTRIBUTORS AND/OR SUPPLIERS SHALL BE LIMITED TO THE MAXIMUM AMOUNT SET FORTH ABOVE FOR THE PRODUCT THAT IS SUBJECT TO THE PROGRAM. SOME STATES AND/OR JURISDICTIONS DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL DAMAGES, SO THE ABOVE LIMITATIONS OR EXCLUSIONS MAY NOT APPLY TO YOU. THE LIMITATIONS OF LIABILITY SET FORTH ABOVE SHALL APPLY TO THE MAXIMUM EXTENT PERMITTED UNDER APPLICABLE LAW.

ARBITRATION: Read the following arbitration provision (“Provision”) carefully. It limits certain of your rights, including your right to obtain relief or damages through court action.

To begin Arbitration, either you or we must make a written demand to the other party for arbitration for the applicable claim (“Claim”). The Arbitration will take place before a single arbitrator. It will be administered in keeping with the Expedited Procedures of the Commercial Arbitration Rules (“Rules”) of the American Arbitration Association (“AAA”) in effect when the Claim is filed. You may get a copy of these AAA’s Rules by visiting www.adr.org. The filing fees to begin and carry out arbitration will be shared equally between you and us. This does not prohibit the arbitrator from giving the winning party their fees and expenses of the arbitration. Unless you and we agree, the arbitration will take place in the county and state where you live. The Federal Arbitration Act, 9 U.S.C. Ch. 1, et seq., will govern and not any state law on arbitration. YOU AGREE AND UNDERSTAND THAT this arbitration provision means that you give up your right to go to court on any Claim covered by this provision. You also agree that any arbitration proceeding will only consider your Claim. Claims by, or on behalf of, other individuals will not be arbitrated in any proceeding that is considering your Claims. THE DEGREE TO WHICH ARBITRATION CAN BE USED AS A DISPUTE RESOLUTION PROCESS FOR CONSUMER CLAIMS VARIES FROM STATE TO STATE, SO THIS ARBITRATION PROVISION MAY NOT APPLY TO YOU, DEPENDING ON YOUR STATE OF RESIDENCE. In the event this Arbitration provision is not approved by the appropriate state regulatory agency, and/or is stricken, severed, or otherwise deemed unenforceable by a court of competent jurisdiction, you and us specifically agree to waive and forever give up the right to a trial by jury. Instead, in the event any litigation arises between you and us, any such lawsuit will be tried before a judge, and a jury will not be impaneled or struck.